Eur J Pharm Biopharm 2005, 61:134–141.PubMedCrossRef 27. Greenberg GR, Feagan BG, Martin F, #https://www.selleckchem.com/products/mm-102.html randurls[1|1|,|CHEM1|]# Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T: Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994, 331:836–841.PubMedCrossRef 28. Hu LD, Liu Y, Tang X, Zhang Q: Preparation and in vitro/in vivo evaluation of sustained-release metformin hydrochloride pellets. Eur J Pharm Biopharm 2006, 64:185–192.PubMedCrossRef 29. USP The United States Pharmacopeia. The United States Pharmacopeial Convention I, Rockville ed; 1999. 30. Davis SS, Hardy JG, Fara JW: Transit

of pharmaceutical dosage forms through the small intestine. Gut 1986, 27:886–892.PubMedCrossRef 31. Holtmann G, Kelly DG, Sternby B, DiMagno EP: Survival of human pancreatic enzymes during small bowel transit: effect of nutrients, bile acids, and enzymes. Am J Physiol 1997, 273:G553-G558.PubMed 32. Fallingborg J, Pedersen P, Jacobsen BA: Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn’s

disease. Dig Dis Sci 1998, 43:702–705.PubMedCrossRef 33. Washington N, Washington C, Wilson CG: Chapter 7: Drug delivery to Selleck FG 4592 the large intestine and rectum. In Physiological Pharmaceutics. 2nd edition. Edited by: Wilson CG. Taylor & Francis, London; 2001. 34. de Roos NM, de Vries JH, Katan MB: Serum lithium as a compliance marker for food and supplement intake. Am J Clin Nutr 2001, 73:75–79.PubMed 35. Muller-Oerlinghausen B, Berghofer A, Bauer M: Bipolar

disorder. Lancet 2002, 359:241–247.PubMedCrossRef 36. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001, 38:1101–1106.PubMedCrossRef 37. Selby JV, Friedman GD, Quesenberry CP: Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 1990, 131:1017–1027.PubMed 38. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM: Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 2006, 37:1503–1507.PubMedCrossRef Miconazole 39. Shoji A, Yamanaka H, Kamatani N: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004, 51:321–325.PubMedCrossRef 40. Snaith ML, Scott JT: Uric acid clearance in patients with gout and normal subjects. Ann Rheum Dis 1971, 30:285–289.PubMedCrossRef 41. Schumacher HR: The pathogenesis of gout. Cleve Clin J Med 2008,75(Suppl 5):S2-S4.PubMedCrossRef 42. Ames BN, Cathcart R, Schwiers E, Hochstein P: Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis.